{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:34Z","timestamp":1784557054698,"version":"3.55.0"},"reference-count":12,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,6]]},"abstract":"Summary<\/jats:title>\n \n A 54-year-old man had gastrinoma, parathyroid hyperplasia and pituitary tumor. His family history indicated that he might have multiple endocrine neoplasia type 1 (MEN1).\n MEN1<\/jats:italic>\n gene analysis revealed a heterozygous germline mutation (Gly156Arg). Therefore, we diagnosed him with MEN1. Endocrinological tests revealed that his serum prolactin (PRL) and plasma adrenocorticotropic hormone (ACTH) levels were elevated to 1699\u2009ng\/mL and 125\u2009pg\/mL respectively. Immunohistochemical analysis of the resected pancreatic tumors revealed that the tumors did not express ACTH. Overnight 0.5 and 8\u2009mg dexamethasone suppression tests indicated that his pituitary tumor was a PRL-ACTH-producing plurihormonal tumor. Before transsphenoidal surgery, cabergoline was initiated. Despite no decrease in the volume of the pituitary tumor, PRL and ACTH levels decreased to 37.8\u2009ng\/mL and 57.6\u2009pg\/mL respectively. Owing to the emergence of metastatic gastrinoma in the liver, octreotide was initiated. After that, PRL and ACTH levels further decreased to 5.1\u2009ng\/mL and 19.7\u2009pg\/mL respectively. He died from liver dysfunction, and an autopsy of the pituitary tumor was performed. In the autopsy study, histopathological and immunohistochemical (IHC) analysis showed that the tumor was single adenoma and the cells were positive for ACTH, growth hormone (GH), luteinizing hormone (LH) and PRL. RT-PCR analysis showed that the tumor expressed mRNA encoding all anterior pituitary hormones, pituitary transcription factor excluding estrogen receptor (ER) \u03b2, somatostatin receptor (SSTR) 2, SSTR5 and dopamine receptor D (D2R). PRL-ACTH-producing tumor is a very rare type of pituitary tumor, and treatment with cabergoline and octreotide may be useful for controlling hormone levels secreted from a plurihormonal pituitary adenoma, as seen in this case of MEN1.\n <\/jats:p>\n \n Learning points:<\/jats:title>\n \n \n Although plurihormonal pituitary adenomas were reported to be more frequent in patients with MEN1 than in those without, the combination of PRL and ACTH is rare.<\/jats:p>\n <\/jats:list-item>\n \n RT-PCR analysis showed that the pituitary tumor expressed various pituitary transcription factors and IHC analysis revealed that the tumor was positive for PRL, ACTH, GH and LH.<\/jats:p>\n <\/jats:list-item>\n \n Generally, the effectiveness of dopamine agonist and somatostatin analog in corticotroph adenomas is low; however, if the plurihormonal pituitary adenoma producing ACTH expresses SSTR2, SSTR5 and D2R, medical therapy for the pituitary adenoma may be effective.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-17-0027","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T06:17:44Z","timestamp":1491459464000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":5,"title":["Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy"],"prefix":"10.1530","volume":"2017","author":[{"given":"Shinsuke","family":"Uraki","sequence":"first","affiliation":[{"name":"1The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ariyasu","sequence":"additional","affiliation":[{"name":"1The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Doi","sequence":"additional","affiliation":[{"name":"1The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Furuta","sequence":"additional","affiliation":[{"name":"1The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nishi","sequence":"additional","affiliation":[{"name":"1The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Usui","sequence":"additional","affiliation":[{"name":"2Department of Medical Genetics, Shizuoka General Hospital, Shizuoka City Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaue","sequence":"additional","affiliation":[{"name":"3The 2nd Department of Surgery, Wakayama Medical University, Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akamizu","sequence":"additional","affiliation":[{"name":"1The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"key20170421170318455_bib1","doi-asserted-by":"publisher","unstructured":"KouvarakiMALeeJEShapiroSEGagelRFShermanSISellinRVCoteGJEvansDB 2002 Genotype-phenotype analysis in multiple endocrine neoplasia type. Archives of Surgery 137 641\u2013647. (doi:10.1001\/archsurg.137.6.641)","DOI":"10.1001\/archsurg.137.6.641"},{"key":"key20170421170318455_bib2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verg\u00e8s","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"key20170421170318455_bib3","first-page":"168","article-title":"Pituitary tumor registry: a novel clinical resource","volume":"85","author":"Drange","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"key20170421170318455_bib4","first-page":"69","article-title":"Plurihormonal pituitary adenomas","volume":"3","author":"Scheithauer","year":"1986","journal-title":"Seminars in Diagnostic Pathology"},{"key":"key20170421170318455_bib5","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31815ade45","article-title":"Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients","volume":"32","author":"Trouillas","year":"2008","journal-title":"American Journal of Surgical Pathology"},{"key":"key20170421170318455_bib6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1507\/endocrj.41.171","article-title":"A case of ectopic ACTH syndrome associated with Zollinger-Ellison syndrome: long-term survival with chemical adrenalectomy","volume":"41","author":"Ishido","year":"1994","journal-title":"Endocrine Journal"},{"key":"key20170421170318455_bib7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cancergen.2015.12.002","article-title":"Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years","volume":"209","author":"Concolino","year":"2016","journal-title":"Cancer Genetics"},{"key":"key20170421170318455_bib8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/BF03343983","article-title":"Macroprolactinoma associated with Cushing\u2019s disease, successfully treated with cabergoline","volume":"25","author":"T\u2019Sjoen","year":"2002","journal-title":"Journal of Endocrinological Investigation"},{"key":"key20170421170318455_bib9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1152\/physrev.00006.2006","article-title":"Molecular physiology of pituitary development: signaling and transcriptional networks","volume":"87","author":"Zhu","year":"2007","journal-title":"Physiological Reviews"},{"key":"key20170421170318455_bib10","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"key20170421170318455_bib11","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1210\/jc.2008-2101","article-title":"Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas","volume":"94","author":"de Bruin","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"key20170421170318455_bib12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1210\/jc.2012-3126","article-title":"Medical treatment of Cushing\u2019s disease","volume":"98","author":"Feelders","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2017\/1\/EDM17-0027.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2017\/1\/EDM17-0027.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:32Z","timestamp":1784555192000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,6]]},"references-count":12,"URL":"https:\/\/doi.org\/10.1530\/edm-17-0027","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,6]]}}}